Nitazoxanide

Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology

Editorial Accompanies Manuscript in March Issue TAMPA, Fla., March 2 /PRNewswire/ -- A study evaluating nitazoxanide in combination with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV) infection with genotype 4 was published in the March issue of Gastroen...

Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C

Data to be Presented at AASLD Meeting TAMPA, Fla., Nov. 2 /PRNewswire/ -- Romark Laboratories, a privately-owned biotechnology company, today announced results of a randomized phase II clinical trial showing that 79% of interferon-naive patients with chronic hepatitis C genoty...

IDEXX Laboratories Announces Fourth Quarter and Full Year Results

... million write-down of raw materials inventory and a $1.0 million write-off of a prepaid royalty license associated with Navigator(R) paste, a nitazoxanide product for the treatment of equine protozoal myeloencephalitis. We wrote down these assets in the second quarter of 2007 because the third-pa...

Nitazoxanide, potent drug to plug the purge caused by rotavirus

... nitazoxanide holds immense promise for kids infected with Rotav...search in Tampa, Florida, compared the efficacy of nitazoxanide administered twice a day for three days vis a vis...suffering severe diarrhea. The study revealed that nitazoxanide was capable of remedying the illness in about 30 h...

Child Diarrhoea Due To Rotavirus:Quick Relief By Short Course Drug

... According to Jean-Francois Rossignol , of The Romark Institute for Medical Research in Tampa, Florida., the results are encouraging. Effects of nitazoxanide administered twice a day for three days were compared with a placebo in 50 children with severe diarrhoea , at the Cairo University Children's Hospi...

A New Drug Promises To Be Very Effective In The Management Of Diarrhea

...02, is the first new drug for treating gastrointestinal infections in children for more than 40 years. Rossignol made a study comparing the effects of nitazoxanide twice a day for three days, with a placebo given to 50 children with severe diarrhea who had all been admitted last summer at the Cairo University Chi...

Nitazoxanide in Medical Technology

Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders

TAMPA, Fla., May 21 /PRNewswire/ -- Romark Laboratories, L.C., a privately-owned biopharmaceutical company, today announced the completion of enrollment into its Phase II clinical trial to evaluate the safety and efficacy of nitazoxanide in combination with standard of care therapy in U.S. pat...

Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008

Findings Include 80% SVR12 Rate with Nitazoxanide-Based Combination Therapy and New Insights into Mechanism of Action of Nitazoxanide MILAN, Italy, April 23 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced that data from studies of nitazoxani...

Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1

Trial Marks Third Study in Company's STEALTH C Clinical Program to Evaluate Nitazoxanide in the Treatment of Chronic Hepatitis C TAMPA, Fla., April 18 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced that it has begun enrolling patients in...

Romark Laboratories Raises $18 Million in Institutional Financing

...ion thiazolide drug candidates for the treatment of hepatitis B and C and other viral diseases. Romark is currently conducting a U.S. Phase 2 trial of nitazoxanide in hepatitis C patients who have failed standard treatments, and expects to begin a U.S. Phase 2 trial in treatment naive patients in the first quarte...

Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States

...n and Chief Science Officer of Romark who invented nitazoxanide and is leading its clinical development. "We are e...d Dr. Rossignol who is also a Stanford affiliate. nitazoxanide is the first of a new class of small molecule drug...lication. Data related to the in vitro activity of nitazoxanide against virus replication in hepatitis C virus (HC...

Nitazoxanide in Biological Technology

Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

Chugai Pharmaceutical Gains Rights to Develop and Market Nitazoxanide for the Treatment of Chronic Hepatitis C TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical Co. Ltd., a member of the Roche Group, today announced...

Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C

Studies presented at the 19th Conference of the Asian Pacific Association for the Study of the Liver (APASL) Demonstrated Favorable Pharmacokinetics and Significant Reduction in Viral Load TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, to...

Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008

Findings Include 80% SVR Rate with Nitazoxanide-Based Combination Therapy and New Insights into Mechanism of Action of Nitazoxanide SAN FRANCISCO, Nov. 3 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced that data from studies of nitazoxanide in...

Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco

Company Also Announces Completion of Enrollment in U.S. Phase II Study of Nitazoxanide in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 TAMPA, Fla., Oct. 28 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced the presentation of stu...

Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer

...gy and gastroenterology will be invaluable as we advance the development of nitazoxanide and other thiazolides for treating viral hepatitis and other digestive dise...tious diseases, cancers, and autoimmune diseases. The Company is developing nitazoxanide for treating chronic hepatitis C and is developing other new thiazolides fo...

Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States

...n and Chief Science Officer of Romark who invented nitazoxanide and is leading its clinical development. "We are e...d Dr. Rossignol who is also a Stanford affiliate. nitazoxanide is the first of a new class of small molecule drug...lication. Data related to the in vitro activity of nitazoxanide against virus replication in hepatitis C virus (HC...